Shares of Pain Therapeutics, Inc. (NASDAQ:PTIE) have been assigned an average broker rating score of 5.00 (Strong Sell) from the one analysts that cover the company, Zacks Investment Research reports. One equities research analyst has rated the stock with a strong sell rating.
Zacks has also given Pain Therapeutics an industry rank of 95 out of 255 based on the ratings given to its competitors.
Several analysts recently commented on PTIE shares. Zacks Investment Research upgraded Pain Therapeutics from a “hold” rating to a “buy” rating and set a $8.25 price target for the company in a research report on Wednesday, March 14th. ValuEngine cut Pain Therapeutics from a “sell” rating to a “strong sell” rating in a research report on Thursday, March 1st.
A hedge fund recently raised its stake in Pain Therapeutics stock. Northern Trust Corp increased its position in shares of Pain Therapeutics, Inc. (NASDAQ:PTIE) by 152.9% in the 1st quarter, according to its most recent disclosure with the SEC. The institutional investor owned 38,144 shares of the biopharmaceutical company’s stock after purchasing an additional 23,062 shares during the quarter. Northern Trust Corp owned approximately 0.55% of Pain Therapeutics worth $270,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 32.97% of the company’s stock.
Shares of Pain Therapeutics opened at $8.23 on Friday, MarketBeat Ratings reports. The company has a market cap of $63.99 million, a PE ratio of -4.52 and a beta of 2.69. Pain Therapeutics has a 1-year low of $3.10 and a 1-year high of $12.80.
Pain Therapeutics (NASDAQ:PTIE) last issued its quarterly earnings results on Wednesday, May 9th. The biopharmaceutical company reported ($0.33) EPS for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.66) by $0.33. research analysts anticipate that Pain Therapeutics will post -1.65 earnings per share for the current year.
About Pain Therapeutics
Pain Therapeutics, Inc develops drugs for nervous system disorders in the United States. The company's lead drug candidate is REMOXY, a proprietary abuse-deterrent oral formulation of oxycodone to treat severe chronic pain. It is also developing FENROCK, a proprietary abuse-deterrent transdermal pain patch for pain relief; PTI-125, a small molecule drug candidate to treat Alzheimer's disease; and PTI-125DX, a blood-based diagnostic/biomarker to detect Alzheimer's disease.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Pain Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pain Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.